» Articles » PMID: 20162460

Parenchyma-preserving Resections for Small Nonfunctioning Pancreatic Endocrine Tumors

Overview
Journal Ann Surg Oncol
Publisher Springer
Specialty Oncology
Date 2010 Feb 18
PMID 20162460
Citations 62
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Parenchyma-preserving resections (PPRs), including enucleation and middle pancreatectomy (MP), are accepted procedures for insulinomas, but their role in the treatment of nonfunctioning pancreatic endocrine tumors (NF-PETs) is debated. The aim of this study was to evaluate perioperative and long-term outcomes after PPRs for NF-PETs.

Methods: All patients who underwent PPRs for NF-PETs between 1990 and 2005 were included. Patients with multiple endocrine neoplasia type 1 were excluded.

Results: Overall, 50 patients (23 men, 27 women, median age 59 years) underwent 26 enucleations and 24 MP. A total of 58% of NF-PETs were incidentally discovered. Median size of the tumors was 13.5 mm with no preoperative suspicion of malignancy in all patients. Overall morbidity and pancreatic fistula rates were 58 and 50%, respectively. Reoperation rate was 4%, with no mortality. Postoperative complications were higher in the MP group. At pathology, there were 34 (68%) benign lesions, 13 (26%) neoplasms of uncertain behavior, and 3 (6%) well-differentiated carcinomas. Forty-one patients (82%) had tumors < or =2 cm in size. Only eight patients (16%) had at least one lymph node removed. After a median follow-up of 58 months, no patient died of disease. Overall, four patients (8%) experienced tumor recurrence after a mean of 68 months. The incidence of exocrine/endocrine insufficiency was 8%.

Conclusions: PPRs are generally safe and effective procedures for treating small NF-PETs. However, better selection criteria must be identified, and lymph node sampling should be performed routinely to avoid understaging. Long-term follow-up evaluation (>5 years) is of paramount importance given the possible risk of late recurrence.

Citing Articles

Impact of Regional Metastasis on Survival for Patients with Nonfunctional Pancreatic Neuroendocrine Tumors: A Systematic Review.

Clarke C, Ward E, Henry V, Nimmer K, Phan A, Evans D Ann Surg Oncol. 2024; 31(8):4976-4985.

PMID: 38652199 DOI: 10.1245/s10434-024-15249-1.


A Rare Cause of Hypoglycemia in Elderly Patients: Insulinoma.

Dirim A, Seker A Cureus. 2024; 16(2):e54002.

PMID: 38476778 PMC: 10928961. DOI: 10.7759/cureus.54002.


Approaching Small Neuroendocrine Tumors with Radiofrequency Ablation.

Rossi G, Petrone M, Healey A, Arcidiacono P Diagnostics (Basel). 2023; 13(9).

PMID: 37174952 PMC: 10177414. DOI: 10.3390/diagnostics13091561.


Efficacy and Safety of Endoscopic Ultrasound-Guided Radiofrequency Ablation for Pancreatic Neuroendocrine Tumors: A Systematic Review and Metanalysis.

Armellini E, Facciorusso A, Crino S Medicina (Kaunas). 2023; 59(2).

PMID: 36837560 PMC: 9963038. DOI: 10.3390/medicina59020359.


Reconsideration of operative indications in pancreatic neuroendocrine neoplasms.

Abe K, Kitago M, Iwasaki E, Yagi H, Abe Y, Hasegawa Y World J Surg Oncol. 2022; 20(1):366.

PMID: 36397094 PMC: 9673351. DOI: 10.1186/s12957-022-02834-5.